Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Seminars in Radiation Oncology 1993-Oct

New Directions in Radionuclide Sources for Brachytherapy.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
Nath

キーワード

概要

Brachytherapy continues to play an important role in the management of cancers of several sites, including the head and neck, brain, uterine cervix, endometrium, and prostate. The physical advantages of brachytherapy result from a superior localization of dose to the tumor volume. In brachytherapy, as radiation is continuously delivered over a period of time, repair of sublethal and potentially lethal damage, proliferation, and other cell kinetic effects modify the response of tumor and normal tissues, resulting in complex dose rate effects that also influence the therapeutic ratio for brachytherapy. There are two different forms of brachytherapy. There are two different forms of brachytherapy: intracavitary irradiation using radioactive sources that are placed in body cavities in close proximity to the tumor, and interstitial brachytherapy using radioactive seeds implanted directly into tumor volume. Intracavitary radiation is always temporary and usually takes about 1 to 4 days. On the other hand, interstitial brachytherapy can be temporary or permanent. Radioactive sources emtting higher energy photons have better tissue penetration but are more difficult to shield for radiation protection purposes than sources emitting lower energy photons. Longer-lived radioactive sources can be used several times in different patients, which reduces their effective cost compared with shorter-lived radioisotopes. However, for permanent implants, shorter-lived radionuclides can provide higher initial dose rate, which may have biological advantages in some cases. These characteristics of various forms of brachytherapy dictate the choice of radioactive sources for a specific treatment. Recently, a number of new radionuclide sources have been developed, making a wide variety of half-lives and photon energies available to the brachytherapy community. Conventional sources for brachytherapy in the United States are cesium 137, iridium 192, iodine 125, and gold 198. The physical characteristics of these sources and of the newly developed sources, americium 241, palladium 103, samarium 145, and ytterbium 169, are described.

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge